GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Cameroon received its first shipment of Mosquirix malaria vaccines manufactured by British drugmaker GSK Plc late on Tuesday, as the nation struggles with the mosquito-borne disease that kills more than 600,000 each year globally.

Cameroon receives first shipment of GSK's Mosquirix malaria vaccine

Broadstone Net Lease

Bank of Nova Scotia

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Diageo

Haleon PLC

Illinois Tool Works

Leggett & Platt

McDonald's

MDU Resources Group

Medical Properties Trust

NetApp

Realty Income Corp

Orion Office REIT

Paramount Global

Philip Morris

Invesco S&P 500 High Dividend Low Volatility ETF

TotalEnergies SE

Visa

Vanguard Dividend Appreciation ETF

Vanguard S&P 500 ETF

Growing dividend income takes time and consistency. The Fed paused a rate hike in September and will likely remain in a holding pattern for November, with a modest chance of an increase in December. Increase passive income by consistently investing in the market and letting dividend reinvestment do the trick.

Dividend Income Summary: Lanny's October 2023 Summary

Cardinal Health

Chubb

Johnson Controls

Kimberly-Clark

Coca-Cola

Mondelez

Altria

Without rehashing the wild ride we experienced in the market the last couple of months with triple digit gains and losses, I could find comfort in one thing, my dividends. Dividends may not increase every year and a cut or elimination is even possible, but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. Another four-digit month came in this year. As you can imagine, I am quite happy seeing that.

Dividend Income Update October 2023

GSK PLC (LSE:GSK, NYSE:GSK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug, momelotinib, a treatment for the rare blood cancer myelofibrosis. This thumbs-up is a crucial step towards the drug's potential approval in the European Union (EU).

GSK receives EU regualtory boost for bone marrow cancer drug

British drugmaker GSK on Monday said the human medicines committee of the European Medicines Agency had recommended approving its oral therapy to treat anaemia in patients with a type of bone marrow cancer called myelofibrosis.

EU regulator backs GSK's bone marrow cancer therapy

Arexvy, GSK's recently launched respiratory syncytial virus (RSV) vaccine, has made a strong start but management remained cautious given the recent launch and broker Berenberg says this is understandable. Berenberg has several questions on Arexvy and shingles vaccine Shingrix but says GSK trades on a compelling valuation currently compared to its pharma peers.

GSK valuation remains compelling vs pharma, says broker

GlaxoSmithKline Pharmaceuticals reported a 12.5% rise in quarterly profit on Thursday as the Indian unit of UK's GSK plc saw strong demand for its vaccines and general medicine.

GSK's India unit posts Q2 profit rise on strong vaccine demand

GSK NYSE: GSK is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to go before the impact is felt, and is well on track to grow now and replace the lost revenue when patent expiry comes.

GSK is a remedy for the winter investment blahs

DexCom

Tenet Healthcare

A record number of Americans are now turning 65, Forbes recently reported, amid tens of millions of Baby Boomers. In fact, according to one report, 76.4 million Baby Boomers are living in America currently.

3 Healthcare Stocks Getting Help From the Aging Population

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?

GSK PLC (LSE:GSK, NYSE:GSK)'s seemingly positive earnings release on Wednesday has been labelled as just that by Stifel analysts, who were left mulling reasons for a subsequent drop in its share price. Though GSK lifted its full-year guidance following strong third-quarter trading, Wednesday's update actually prompted a 2% slide in the pharmaceuticals giant's shares.

GSK falls victim of ‘hard to please' pharma market

Caterpillar

For conservative investors, including those in and nearing retirement, highly reliable dividend stocks with a growth component are an excellent tool. That's because these equities produce regular income and are likely to generate significant returns for investors through increases in their stock prices.

3 Top Dividend Stock Picks for Steady Income and Capital Appreciation

GSK plc (NYSE:GSK ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Julie Brown - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Kerry Holford - Berenberg Simon Baker - Redburn Andrew Baum - Citi Richard Parkes - BNP Paribas James Gordon - JPMorgan Mark Purcell - Morgan Stanley Steve Scala - TD Cowen Peter Welford - Jefferies Emily Field - Barclay Nick Stone Hello, everyone. It's Nick Stone, Head of Investor Relations.

GSK plc (GSK) Q3 2023 Earnings Call Transcript

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively strong third-quarter performance and raised financial guidance. Shore Capital Markets praise the “stellar debut” of respiratory syncytial virus vaccine Arexvy, which helped to drive up vaccine sales 13% over targets.

GSK receives a mixed City reaction despite raised outlook

GSK raised its outlook for the second time this year on the back of a strong launch for its RSV vaccine. But GSK stock fell.

GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch

GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.09 per share a year ago.

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.

GSK Boosts Profit Forecasts After ‘Outstanding' RSV Vaccine Launch

GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respiratory treatment in the US. The pharmaceuticals company expects full-year turnover to increase by 12% to 13%, up from 8% to 10% before, with adjusted operating profit growth between 13% to 15%, up from 11% to 13% previously.

GSK raises outlook amid strong demand for new RSV vaccine

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot.

GSK raises annual forecasts again on strong Arexvy launch

The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.

GSK Reports Earnings Wednesday. What to Watch.

Johnson & Johnson

British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.

GSK signs $1 bln deal for exclusive license to J&J's hepatitis B therapy

Pfizer

Pfizer , which dominated COVID vaccine sales, now finds itself looking up at GSK , whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.

Pfizer RSV vaccine lags GSK's as head-to-head competition underway

British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.

GSK says endometrial cancer drug meets primary goal in late-stage trial

Bionano Genomics

One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks at this point.

3 Deeply Undervalued Growth Stocks

News for GlaxoSmithKline Stock (GSK)